4.945
前日終値:
$4.95
開ける:
$4.95
24時間の取引高:
359.32K
Relative Volume:
0.50
時価総額:
$297.81M
収益:
-
当期純損益:
$-44.80M
株価収益率:
-6.5933
EPS:
-0.75
ネットキャッシュフロー:
$-30.67M
1週間 パフォーマンス:
-5.54%
1か月 パフォーマンス:
-6.08%
6か月 パフォーマンス:
+128.70%
1年 パフォーマンス:
+5.11%
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
名前
Aldeyra Therapeutics Inc
セクター
電話
781-761-4904
住所
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics Inc
|
4.94 | 297.81M | 0 | -44.80M | -30.67M | -0.75 |
|
ARGX
Argen X Se Adr
|
922.01 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.58 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.15 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
365.33 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
721.19 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-03 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 再開されました | H.C. Wainwright | Buy |
| 2022-04-27 | 再開されました | H.C. Wainwright | Buy |
| 2021-02-08 | 開始されました | H.C. Wainwright | Buy |
| 2020-12-16 | 開始されました | Berenberg | Buy |
| 2020-10-30 | 開始されました | Jefferies | Buy |
| 2020-10-16 | 開始されました | BTIG Research | Buy |
| 2020-09-22 | 開始されました | Alliance Global Partners | Buy |
| 2020-05-12 | 開始されました | Oppenheimer | Outperform |
| 2018-12-04 | 開始されました | Citigroup | Buy |
| 2018-09-26 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 開始されました | Janney | Buy |
| 2018-01-26 | 開始されました | Seaport Global Securities | Buy |
| 2016-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2016-07-01 | 開始されました | Stifel | Buy |
| 2015-07-01 | 開始されました | Canaccord Genuity | Buy |
| 2015-03-25 | 開始されました | Chardan Capital Markets | Buy |
| 2015-03-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2014-11-18 | 開始されました | H.C. Wainwright | Buy |
| 2014-06-19 | 開始されました | Aegis Capital | Buy |
すべてを表示
Aldeyra Therapeutics Inc (ALDX) 最新ニュース
Live market analysis of Aldeyra Therapeutics Inc.Treasury Yields & Fast Gaining Stock Reports - newser.com
Aldeyra Therapeutics Inc. stock daily chart insightsFed Meeting & Safe Capital Growth Stock Tips - newser.com
Why Aldeyra Therapeutics Inc. stock is in analyst buy zone2025 Price Action Summary & Low Drawdown Trading Strategies - newser.com
Sentiment analysis tools applied to Aldeyra Therapeutics Inc.July 2025 Recap & Weekly Market Pulse Alerts - newser.com
Smart tools for monitoring Aldeyra Therapeutics Inc.’s price actionWeekly Trading Summary & AI Forecast Swing Trade Picks - newser.com
Applying Wyckoff theory to Aldeyra Therapeutics Inc. stock2025 AllTime Highs & Growth Focused Entry Reports - newser.com
Aldeyra Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Closing Moves & Low Risk Investment Opportunities - newser.com
What to expect from Aldeyra Therapeutics Inc. in the next 30 daysTrade Ideas & Weekly Top Gainers Trade List - newser.com
How Aldeyra Therapeutics Inc. stock performs in weak economyMarket Trend Summary & Entry Point Confirmation Alerts - newser.com
Intraday pattern recognizer results for Aldeyra Therapeutics Inc.2025 Price Targets & Smart Money Movement Alerts - newser.com
Can a trend reversal in Aldeyra Therapeutics Inc. lead to recoveryLayoff News & Stock Timing and Entry Methods - newser.com
Is Aldeyra Therapeutics Inc. stock resilient to inflation2025 Market Sentiment & Accurate Intraday Trade Tips - Fundação Cultural do Pará
Is Aldeyra Therapeutics Inc. stock dividend yield sustainableQuarterly Market Summary & Pattern Based Trade Signal System - Fundação Cultural do Pará
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research and Development Webcast - MarketScreener
Is Aldeyra Therapeutics Inc. stock affected by interest rate hikesPortfolio Update Report & Free Expert Verified Stock Movement Alerts - newser.com
Aldeyra expands RASP platform to include neuroinflammatory diseases By Investing.com - Investing.com Nigeria
Understanding Aldeyra Therapeutics Inc.’s price movementQuarterly Performance Summary & Consistent Return Investment Signals - newser.com
Automated trading signals detected on Aldeyra Therapeutics Inc.Dip Buying & Stepwise Trade Execution Plans - newser.com
Analyzing net buyer seller activity in Aldeyra Therapeutics Inc.Risk Management & Real-Time Buy Signal Alerts - newser.com
ALDX: ADX-248 advances in CNS and immune diseases as reproxalap nears FDA approval, with strong financials - TradingView
Published on: 2025-11-13 12:25:09 - newser.com
Aldeyra (ALDX) Expands RASP Platform to Target Neuroinflammatory Diseases - GuruFocus
Aldeyra Therapeutics announces expansion of rasp platform - MarketScreener
Aldeyra expands RASP platform to include neuroinflammatory diseases - Investing.com India
Aldeyra Therapeutics Expands RASP Platform and Updates on Reproxalap - TradingView
Key FDA Verdict Looms for Aldeyra’s Lead Drug Candidate - AD HOC NEWS
Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI - Stock Titan
Aldeyra Therapeutics Inc (ALDX) 財務データ
収益
当期純利益
現金流量
EPS
Aldeyra Therapeutics Inc (ALDX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Machatha Stephen | Chief Development Officer |
Aug 11 '25 |
Sale |
5.15 |
22,073 |
113,713 |
221,799 |
大文字化:
|
ボリューム (24 時間):